Trial Profile
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Dubermatinib (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology; Tolero Pharmaceuticals
- 06 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 10 Mar 2020 Planned End Date changed from 1 Apr 2021 to 1 Jun 2020.
- 10 Mar 2020 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2020.